Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Chest ; 115(4): 1207-10, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10208234

ABSTRACT

Intravascular lymphomatosis (IVL) is a rare lymphoid neoplasm that is typically of B-cell lineage and characterized by proliferation of malignant cells within small arterioles, capillaries, and venules. We report a patient with pulmonary IVL who presented clinically with progressive dyspnea, fever, and a dry cough. Pulmonary function tests revealed a marked decrease in diffusion capacity with airflow obstruction and severe air trapping. High-resolution CT (HRCT) of the chest with inspiratory and expiratory images revealed mosaic attenuation consistent with air trapping. Transbronchial biopsies revealed the diagnosis of IVL with capillary expansion in the alveolar and peribronchiolar interstitial tissue. IVL should be considered in the differential diagnosis of a patient with an interstitial lung disease, air trapping on pulmonary function tests, and mosaic attenuation on HRCT. Transbronchial biopsies may be the initial diagnostic procedure of choice.


Subject(s)
Lung Neoplasms/diagnosis , Lymphoma, Non-Hodgkin/diagnosis , Vascular Neoplasms/diagnosis , Dyspnea/etiology , Humans , Lung/blood supply , Lung/diagnostic imaging , Lung Neoplasms/complications , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/pathology , Lymphoma, Non-Hodgkin/complications , Lymphoma, Non-Hodgkin/diagnostic imaging , Lymphoma, Non-Hodgkin/pathology , Male , Middle Aged , Tomography, X-Ray Computed , Vascular Neoplasms/complications , Vascular Neoplasms/diagnostic imaging , Vascular Neoplasms/pathology
2.
Ann Intern Med ; 128(12 Pt 1): 975-81, 1998 Jun 15.
Article in English | MEDLINE | ID: mdl-9625683

ABSTRACT

BACKGROUND: Hepatic complications are a major cause of illness and death after bone marrow transplantation. OBJECTIVE: To confirm the results of a pilot study that indicated that ursodiol prophylaxis could reduce the incidence of veno-occlusive disease of the liver. DESIGN: Randomized, double-blind, placebo-controlled study. SETTING: Tertiary care teaching hospital. PATIENTS: 67 consecutive patients undergoing transplantation with allogeneic bone marrow (donated by a relative) in whom busulfan plus cyclophosphamide was used as the preparative regimen and cyclosporine plus methotrexate was used to prevent graft-versus-host disease. INTERVENTION: Before the preparative regimen was started, patients were randomly assigned to receive ursodiol, 300 mg twice daily (or 300 mg in the morning and 600 mg in the evening if body weight was > 90 kg), or placebo. MEASUREMENTS: Patients were prospectively evaluated for the clinical diagnosis of veno-occlusive disease, the occurrence of acute graft-versus-host disease, and survival. RESULTS: The incidence of veno-occlusive disease was 40% (13 of 32 patients) in placebo recipients and 15% (5 of 34 patients) in ursodiol recipients (P = 0.03). Assignment to placebo was the only pretransplantation characteristic that predicted the development of veno-occlusive disease. The most significant predictor of 100-day mortality was the diagnosis of veno-occlusive disease. The difference in actuarial risk for hematologic relapse in patients with chronic myelogenous leukemia and nonhepatic toxicities between the two groups was not statistically significant (13% in the ursodiol group and 20% in the placebo group; P > 0.2). CONCLUSION: Ursodiol prophylaxis seemed to decrease the incidence of hepatic complications after allogeneic bone marrow transplantation in patients who received a preparative regimen with busulfan plus cyclophosphamide.


Subject(s)
Bone Marrow Transplantation/adverse effects , Cholagogues and Choleretics/therapeutic use , Hepatic Veno-Occlusive Disease/prevention & control , Ursodeoxycholic Acid/therapeutic use , Adult , Bone Marrow Transplantation/mortality , Busulfan/therapeutic use , Cyclophosphamide/therapeutic use , Double-Blind Method , Drug Therapy, Combination , Female , Graft vs Host Disease/prevention & control , Humans , Immunosuppressive Agents/therapeutic use , Male , Middle Aged , Placebos , Survival Rate , Transplantation, Homologous
3.
Am J Kidney Dis ; 17(5): 581-4, 1991 May.
Article in English | MEDLINE | ID: mdl-2024660

ABSTRACT

Hypernatremic dehydration due to unreplaced stool water losses often complicates the use of the osmotic cathartic lactulose in the treatment of hepatic encephalopathy. Sorbitol, another osmotic cathartic commonly used in the treatment of drug intoxications, has been reported in the pediatric literature to induce severe hypernatremia, but there is only a rare case report in an adult. We report a dramatic case of severe hypernatremia secondary to repetitive administration of activated charcoal-sorbitol suspension for the treatment of phenobarbital intoxication in an adult. Based on our experience with this case, several recommendations are provided regarding management of drug intoxications with charcoal-sorbitol suspension, including meticulous attention to fluid-electrolyte balance, type of replacement fluid, and dosing of the suspension.


Subject(s)
Cathartics/adverse effects , Hypernatremia/chemically induced , Sorbitol/adverse effects , Adult , Cathartics/administration & dosage , Charcoal/administration & dosage , Female , Humans , Phenobarbital/poisoning , Poisoning/therapy , Sorbitol/administration & dosage , Suspensions
SELECTION OF CITATIONS
SEARCH DETAIL
...